PainChek General Discussion, page-8557

AIM8OT, yes I agree broadly with you, but just to flesh out a few things which can make for a big difference to the final outcome, I offer the following:
PD’s 35k - 45k beds was Aust alone
we need to factor in a 80% GP
Overseas marketing costs won’t be cheap - but given the stickiness of the recurring revenue, marketing is really an investment in future revenue.
To stay ahead of the pack, significant money has to be invested in R&D. PCK should look to become the world’s leading analysts of pain & discomfort that creates a reliable standard used by all medical staff for all patient types, not just dementia sufferers.